Sponsor:Shanghai Institute of Materia Medica, CAS
Dean:Jiang Hualiang,academician
Executive dean:Huang Wei
Academician list: Ding Jian, Jiang Hualiang
The school construction goal is based on the principle of “adhering to first-class standards, combining major needs, meeting national plans, strengthening dynamic monitoring and strengthening performance-related incentives”. The school will be built into a new drug development institution and pharmaceutical personnel training base, with “special features, interdisciplinary type, high level and internationalization”.

School of Pharmaceutical Science and Technology |
Research Center for Medicinal Chemistry |
Research Center for Chemical Biology |
Research Center for Tumor Pharmacology |
Research Center for Metabolism and Immunopharmacology |
Prof. Liu Hong workshop Prof. Hu Youhong workshop Prof. Zhou Bing workshop |
Prof. Jiang Hualiang workshop Prof. Yang Caiguang workshop Prof. Huang Wei workshop |
Prof. Ding Jian workshop Prof. Geng Meiyu workshop Prof. Luo Cheng workshop |
Prof. Li Jia workshop Prof. Xie Xin workshop Prof. Wu Beili workshop |
The Research Center for Medicinal Chemistry covers three research fields: small molecule drug and probe discovery, high efficiency synthesis and drug discovery, structure optimization and pharmaceutical study. The Research Center for Chemical Biology covers three research fields: computational chemistry and biology, protein chemical biology and glyco-chemistry biology; The Research Center for Tumor Pharmacology includes three research fields: anti-tumor drug discovery, tumor drug resistance and biomarkers, and anti-tumor drug target.The Research Center for Metabolism and Immunopharmacology covers three research fields of metabolic pharmacology, immunopharmacology, receptor structure and function.
Three major directions for breakthrough
Focus on key technologies for drug design based on big data and artificial intelligence
Discovery and validation for novel drug targets of source innovation
Research and development of new drugs and new therapeutic strategies for tumor, metabolic and immune diseases
Five key development directions
Study on small molecule drugs based on protein-protein interaction
New drug research and development strategy based on bio glycopeptide microchip technology
Disease treatment scheme based on regulation mechanism for intestinal microbiota
Study on mechanism of tumor drug resistance based on multi-system interaction regulation
Cell/gene therapy based on tumor, immune or metabolic diseases